Projekt

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Dif-fuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Abgeschlossen - Rekrutierung – beendet · 2021 bis 2030

Hess Dagmar, Scherrer Julia, Müller Fiona